Loading
Nanoparticle-based Drug Delivery / Gold and Silver Nanoparticles Synthesis and Applications / Nanoplatforms for Cancer Theranostics · Journal article
Pharmaceuticals · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that describes the physicochemical properties of gold nanoparticles and their theoretical applications in prostate cancer therapy, including drug delivery, photothermal therapy, and multimodal imaging. The source acknowledges preclinical and early clinical potential but does not report quantified efficacy data, clinical outcomes, or comparative results; it emphasizes unresolved challenges in toxicity, biodistribution, and manufacturing.
Journal article. Prostate cancer (broad, no specific patient cohort studied).
Gold nanoparticles possess tunable size, shape, and surface plasmon resonance enabling enhanced drug loading and targeted delivery AuNPs have intrinsic optical and photothermal properties suitable for photothermal therapy, radiosensitization, and multimodal imaging (CT and photoacoustic imaging) Functionalization of AuNPs permits active tumor targeting to minimize systemic toxicity
No quantified efficacy, safety, or clinical outcome data reported Functionalization of AuNPs permits active tumor targeting to minimize systemic toxicity
This review may inform researchers and clinicians about emerging nanotechnology platforms in early development for prostate cancer, but does not provide evidence to guide current clinical practice or treatment decisions. Clinical applicability remains uncertain pending resolution of safety and manufacturing concerns.
A narrative review summarizing preclinical and theoretical potential of gold nanoparticles in prostate cancer, without presenting original experimental data, clinical trials, or quantified outcomes.
This review may inform researchers and clinicians about emerging nanotechnology platforms in early development for prostate cancer, but does not provide evidence to guide current clinical practice or treatment decisions. Clinical applicability remains uncertain pending resolution of safety and manufacturing concerns.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Prostate cancer (PC) is one of the most common cancers in men globally and there is an urgent need for new immune-based approaches because many traditional therapies, including chemotherapy, radiotherapy, and anti-androgens, have limitations. Due to their distinct physicochemical and biological features, gold nanoparticles (AuNPs) are emerging as a potential nanoplatform for the development of strategies in prostate cancer therapy. These features include tunable size, shape, and surface plasmon resonance (SPR) and high surface-to-volume ratio, which result in enhanced drug loading, targeted delivery and improved bioavailability. In addition, AuNPs can also be functionalized for active targeting to promote selective accumulation in tumors while minimizing systemic toxicity. In addition, the intrinsic optical and photothermal properties of these nanoparticles allow them to serve for PTT, radiosensitization and multimodal imaging, i.e., CT (computed tomography) and photoacoustic imaging. These have shown potential in pre-clinical and clinical evaluation but face issues with long-term toxicity, biodistribution and large-scale manufacturing. In this review, we summarize the organizing features, functional properties, therapeutic activities and translational potentials of AuNPs in prostate cancer treatment, with emphasis on their contributions towards precision nanomedicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.